Table 1.
Baseline Demographic and Clinical Characteristics
| Patient characteristics | CPP |
Transgender |
pa |
||
|---|---|---|---|---|---|
| Male |
Female |
AMAB |
AFAB |
||
| N=9 (30%) | N=21 (70%) | N=17 (56.7%) | N=13 (43.3%) | p=NS | |
| Age (years) | 9.6±1.0 | 6.3±2.3 | 13.2±2.3 | 12.7±1.8 | <0.001 |
| Ethnicity | |||||
| Non-Hispanic | 5 (56%) | 8 (38%) | 13 (78%) | 10 (77%) | <0.01b |
| Hispanic | 4 (44%) | 13 (62%) | 3 (19%) | 3 (23%) | |
| Unknown | — | — | 1 (2%) | — | |
| Race | |||||
| White or | 6 (67%) | 9 (42%) | 16 (94%) | 13 (100%) | <0.001c |
| Caucasian | 1 (11%) | 4 (19%) | — | — | |
| Black or AA | 1 (11%) | 4 (19%) | — | — | |
| Hispanic | |||||
| American Indian or Alaska Native | — | 1 (5%) | — | — | |
| Other | 1 (11%) | 2 (10%) | — | — | |
| Unknown | — | 1 (5%) | 1 (6%) | — | |
| Tanner stage | |||||
| II | 5 (55%) | 7 (33%) | 5 (29%) | 3 (23%) | <0.001d |
| III | 3 (33%) | 11 (52%) | 3 (18%) | 1 (8%) | |
| IV | 1 (12%) | 3 (14%) | 5 (29%) | 4 (31%) | |
| V | — | — | 4 (23%) | 4 (31%) | |
| Not reported | — | — | — | 1 (8%) | |
| GnRHa type | |||||
| Leuprolide 7.5 mg | — | 5 (24%) | — | — | <0.05e |
| Leuprolide 15 mg | 2 (22%) | 4 (19%) | 2 (12%) | 1 (8%) | |
| Leuprolide 30 mg | 2 (22%) | 6 (29%) | 3 (18%) | 4 (31%) | |
| Supprelin implant | 5 (55%) | 5 (24%) | 8 (47%) | 5 (38%) | |
| Vantas implant | — | 1 (4%) | 4 (23%) | 3 (23%) | |
a
p-values for (total) transgender group versus (total) CPP group.
b
Hispanic versus non-Hispanic.
c
Comparison of White/Caucasian, Black/AA, and Hispanic.
d
Comparison of tanner groups II, III, IV, and V.
e
Use of leuprolide (all doses grouped together) versus histrelin implant (Supprelin and Vantas grouped together).
AA, African American; AFAB, assigned female at birth; AMAB, assigned male at birth; CPP, central precocious puberty; GnRHa, gonadotropin-releasing hormone agonists; NS, not significant.